Literature DB >> 19275044

Macrolide-lincosamide-streptogramin B resistant phenotypes and genotypes for methicillin-resistant Staphylococcus aureus in Turkey, from 2003 to 2006.

H Cem Gul1, Abdullah Kilic, Aylin Uskudar Guclu, Orhan Bedir, Mustafa Orhon, A Celal Basustaoglu.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) strains with inducible macrolide-lincosamide-streptogramin B (iMLS(B)) resistance phenotype may lead to clinical failure during clindamycin (CLI) therapy. The aim of this study was to determine the incidence of MLS(B) phenotypes by using D-test method and genotypes by using multiplex real-time PCR method in MRSA strains. A total of 265 MRSA strains were obtained from clinical samples from hospitalized and outpatients. Of the MRSA isolates, 225 (84.9%) were resistant to erythromycin (ERT), and 170 (64.1%) to CLI. Among the 225 ERT-resistant MRSA strains, the constitutive MLS(B) (cMLS(B)) rate was found in 49.3%, iMLS(B) in 39.1% and the M phenotype in 11.5%. Overall, ermA, ermC, ermA+ermC, msrA, ermC+msrA, and ermA+ermC+msrA genes were detected in 85 (37.7%), 60 (26.6%), 42 (18.6%), 26 (11.5%), 11 (4.8%), and 1 (0.4%) isolates, respectively. Most prevalent resistance determinant in MRSA strains was ermA, which was detected in 37.7% of the isolates. The 26 MRSA strains with M phenotype harboured only msrA gene. In conclusion, due to aware of the potential of CLI treatment failure, D-test should be performed and reported in MRSA strains in clinical laboratories. The multiplex real-time PCR method is easy to perform, fast and reliable method for the detection of MLS(B) resistance genotypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19275044

Source DB:  PubMed          Journal:  Pol J Microbiol        ISSN: 1733-1331


  7 in total

1.  Virulence and resistance determinants of German Staphylococcus aureus ST398 isolates from nonhuman sources.

Authors:  M A Argudín; B-A Tenhagen; A Fetsch; J Sachsenröder; A Käsbohrer; A Schroeter; J A Hammerl; S Hertwig; R Helmuth; J Bräunig; M C Mendoza; B Appel; M R Rodicio; B Guerra
Journal:  Appl Environ Microbiol       Date:  2011-03-04       Impact factor: 4.792

Review 2.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

3.  Prevalence of MLSB Resistance and Observation of erm A & erm C Genes At A Tertiary Care Hospital.

Authors:  Ameer Abbas; Preeti Srivastava; Prem Singh Nirwan
Journal:  J Clin Diagn Res       Date:  2015-06-01

4.  Phenotypic and genotypic study of macrolide, lincosamide and streptogramin B (MLSB) resistance in clinical isolates of Staphylococcus aureus in Tehran, Iran.

Authors:  Horieh Saderi; Behzad Emadi; Parviz Owlia
Journal:  Med Sci Monit       Date:  2011-02

5.  Frequency of genes encoding erythromycin ribosomal methylases among Staphylococcus aureus clinical isolates with different D-phenotypes in Tehran, Iran.

Authors:  Sareh Sadat Hosseini; Mohammad Niakan; Horieh Saderi; Mitra Motallebi; Morovat Taherikalani; Khairollah Asadollahi; Mohammad Emaneini
Journal:  Iran J Microbiol       Date:  2016-06

6.  Molecular characterization and antimicrobial susceptibility of Staphylococcus aureus isolated from children with acute otitis media in Liuzhou, China.

Authors:  Yan Ling Ding; Jinjian Fu; Jichang Chen; Sheng Fu Mo; Shaolin Xu; Nan Lin; Peixu Qin; Eric McGrath
Journal:  BMC Pediatr       Date:  2018-12-15       Impact factor: 2.125

7.  Antimicrobial susceptibility and resistance mechanisms of methicillin resistant Staphylococcus aureus isolated from 12 Hospitals in Turkey.

Authors:  Ömer Yıldız; Ahmet Yılmaz Çoban; Aslı Gamze Şener; Seher Ayten Coşkuner; Gülçin Bayramoğlu; Hüseyin Güdücüoğlu; Mustafa Özyurt; Müşerref Tatman-Otkun; Nihal Karabiber; Nuri Özkütük; Orhan Aktepe; Serkan Öncü; Uğur Arslan; Bülent Bozdoğan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-09-16       Impact factor: 3.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.